Research programme: phosphodiesterase IV inhibitors - VIVUS
Latest Information Update: 10 Dec 2021
At a glance
- Originator VIVUS
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Erectile dysfunction in USA (unspecified route)
- 09 Nov 2000 New profile
- 09 Nov 2000 Preclinical development for Erectile dysfunction in USA (Unknown route)